Archive: Company News
Company News: ISA Pharmaceuticals’ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the start of a Phase II combination trial of its lead compound ISA101b and Pfizer´s 4-1BB agonist Utomilumab, which will be sponsored and conducted by The University of Texas MD Anderson Cancer Center (Houston, TX).
Company News: Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy
Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, and Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, announced today that Mymetics SA, the Swiss subsidiary of Mymetics Corporation and Anergis SA have entered into a Research Collaboration project.
Company News: Curetis to Publish its 2017 Annual Results on April 30, 2018
– Company to host earnings conference call and webcast
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it will publish its full-year 2017 financial results on April 30, 2018. In addition, the Company will host a public earnings conference call and webcast on April 30, 2018, at 03:00 pm CET / 09:00am EDT to present the financial results of 2017, highlight the most important events and provide an outlook for 2018.
Company News: Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
— UTI panel covers 103 diagnostic targets
— 443-patient multi-center study demonstrates overall weighted average sensitivity of 95.6% at an overall weighted average specificity of 99.3%
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced the successful completion of clinical performance evaluation and CE-IVD marking of its novel Unyvero Application Cartridge, UTI, for the diagnosis of severe urinary tract infections. Unyvero UTI will be launched during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Madrid, Spain, from April 21 to 24, 2018.